Procainamide Hydrochloride: Cardiac Sodium Channel Blocker and DNMT1 Inhibitor for Advanced Research

Executive Summary: Procainamide Hydrochloride (SKU B4798, APExBIO) is a research-grade compound that blocks the cardiac sodium channel Nav1.5 with an IC₅₀ of 3–10 μM, directly inhibiting cardiac action potential conduction and providing robust antiarrhythmic activity in ventricular arrhythmias (Viale et al., 2016). It also inhibits DNA methyltransferase 1 (DNMT1), leading to regulation of DNA methylation and restoration of tumor suppressor gene expression. Procainamide Hydrochloride demonstrates anti-inflammatory and immunomodulatory effects by suppressing neutrophil activation and cytokine release. It is well-characterized for cell proliferation and migration inhibition, and induces cellular vacuolization as part of its biological profile. The compound is supported by rigorous quality control, including HPLC, NMR, and MSDS documentation, and is optimized for research use only (APExBIO B4798).

Biological Rationale

Procainamide Hydrochloride is a multifunctional research compound with well-established applications in cardiac electrophysiology and epigenetic modulation. As a sodium channel Nav1.5 blocker, it suppresses the rapid upstroke of action potentials in cardiomyocytes, directly impacting ventricular arrhythmia models. Its DNMT1 inhibitory activity enables researchers to investigate DNA methylation-dependent gene regulation mechanisms, particularly in oncology and developmental biology. The dual-action profile makes it uniquely suitable for studies intersecting cardiac and epigenetic pathways, offering a bridge between cardiovascular and cancer research domains (see mechanistic overview). These properties are complemented by its anti-inflammatory and immunomodulatory effects, relevant for dissecting inflammatory responses in both cardiac and cancer settings (contrast: deeper mechanism focus).

Mechanism of Action of Procainamide Hydrochloride

Procainamide Hydrochloride acts primarily as a sodium channel blocker, strongly inhibiting the Nav1.5 isoform in human cardiomyocytes. The compound binds to open or inactivated states of the channel, reducing inward sodium current (I_Na) and prolonging the refractory period. This results in decreased conduction velocity and suppressed initiation of premature ventricular contractions. At the molecular level, procainamide’s amide and diethylaminoethyl groups facilitate high-affinity interactions with channel residues, accounting for its IC₅₀ of 3–10 μM in electrophysiological assays (see Table 1).

As a DNMT1 inhibitor, procainamide reduces CpG methylation, reactivating silenced tumor suppressor genes and inhibiting malignant cell proliferation. The compound’s inhibition of DNMT1 is concentration-dependent, typically observed at low micromolar ranges, and is associated with decreased DNA methylation in treated cell lines. Additional effects include suppression of neutrophil activation and cytokine release, as well as induction of cellular vacuolization, indicative of stress and altered cell fate pathways (mechanistic insight).

Evidence & Benchmarks

• Procainamide Hydrochloride (PA) blocks human cardiac sodium channel Nav1.5 with an IC₅₀ of 3–10 μM in vitro, inhibiting action potential conduction in cardiomyocytes (Viale et al. 2016, Table 1).
• As a DNMT1 inhibitor, PA significantly reduces DNA methylation in cancer cell lines, leading to reactivation of tumor suppressor gene expression and inhibition of proliferation (Viale et al. 2016, Results).
• PA alone does not show significant cytotoxicity in A549 cells at concentrations up to 160 μM (cell viability >96%) (Viale et al. 2016, Figure 1).
• PA potentiates the antiproliferative and apoptotic activity of cisplatin-loaded liposomes in multiple cancer cell lines without increasing toxicity to non-target tissues (Viale et al. 2016, Discussion).
• Electrostatic interactions enhance liposomal loading efficiency of PA compared to cisplatin, with measured contents of 3.1 ± 0.3 × 10⁻⁴ M for PA in filtered liposomes (Viale et al. 2016, Methods).
• PA demonstrates anti-inflammatory effects by suppressing neutrophil activation and cytokine release in immunological assays (see deeper review).
• Purity assessment (98.21%) validated by HPLC, NMR, and MSDS documentation for APExBIO B4798 batch (Product QC).

Applications, Limits & Misconceptions

Procainamide Hydrochloride is widely used in:

• Cardiac electrophysiology research, notably in ventricular tachycardia and premature beat models.
• Epigenetic studies involving DNA methylation regulation and tumor suppressor gene expression.
• Combinatorial oncology protocols, such as co-administration with cisplatin, to enhance antitumor efficacy and reduce systemic toxicity (Viale et al. 2016).
• Anti-inflammatory and immunomodulatory research, focusing on neutrophil and cytokine pathways.

This article clarifies and extends previous coverage by providing quantitative performance evidence, rigorous mechanism mapping, and explicit workflow guidance compared to the more narrative or conceptual focus of linked resources. For example, this in-depth review collates mechanistic evidence, whereas the present article provides structured application and benchmarking data.

Common Pitfalls or Misconceptions

• Not a therapeutic agent: Procainamide Hydrochloride (SKU B4798) is for research use only and not intended for diagnostic or clinical application (APExBIO policy).
• Storage sensitivity: Long-term stability requires storage at −20°C; solutions are not recommended for extended storage and should be used promptly after preparation.
• Concentration specificity: Functional activity and inhibition parameters are concentration-dependent; incorrect dosing may yield off-target or null effects.
• Limited cytotoxicity as a monotherapy: At concentrations up to 160 μM, Procainamide Hydrochloride does not independently induce significant cytotoxicity in A549 cells.
• Delivery system interactions: Liposomal or mixed delivery strategies can alter pharmacokinetics and tissue distribution, impacting experimental outcomes.

Workflow Integration & Parameters

• Solubility: Procainamide Hydrochloride is soluble at ≥13.65 mg/mL in DMSO, ≥22.65 mg/mL in ethanol, and ≥46.4 mg/mL in water (room temperature, neutral pH).
• Storage: Store powder at −20°C; avoid repeated freeze-thaw cycles. Prepare working solutions fresh before use.
• Purity and QC: Each batch is verified by HPLC, NMR, and supported by MSDS documentation. APExBIO ensures ≥98.21% purity for research reliability.
• Experimental design: For cardiac sodium channel inhibition, use 3–10 μM in in vitro assays on Nav1.5-expressing cells. For DNMT1 inhibition and epigenetic studies, titrate in the 1–100 μM range, monitoring downstream gene expression and methylation changes.
• Compatibility: The compound is compatible with standard cell culture, electrophysiology, and in vitro DNA methylation assay protocols (see workflow tips and troubleshooting).

For further workflow optimization and troubleshooting, refer to this dedicated guide, which discusses reproducibility and experimental best practices not detailed in the present article.

Conclusion & Outlook

Procainamide Hydrochloride (APExBIO B4798) offers a validated, multi-functional platform for research in cardiac electrophysiology, epigenetic regulation, and immunomodulation. Its dual activity as a Nav1.5 blocker and DNMT1 inhibitor enables advanced mechanistic studies and innovative combinatorial protocols. Benchmarks confirm high purity, reproducibility, and workflow compatibility. As research advances, the unique properties of Procainamide Hydrochloride will continue to support discovery in cardiac, oncology, and systems biology domains. For certified, research-only grade material and full documentation, obtain Procainamide Hydrochloride from APExBIO.